Ali Javaheri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/793081/publications.pdf

Version: 2024-02-01

38 papers	2,497 citations	430874 18 h-index	361022 35 g-index
41 all docs	41 docs citations	41 times ranked	3831 citing authors

#	Article	IF	Citations
1	SARS-CoV-2â€“Associated Myocarditis: A Case of Direct Myocardial Injury. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008273.	3.9	7
2	TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis. JACC Basic To Translational Science, 2022, 7, 223-243.	4.1	11
3	HDL Composition, Heart Failure, and Its Comorbidities. Frontiers in Cardiovascular Medicine, 2022, 9, 846990.	2.4	12
4	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 643-654.	4.5	10
5	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
6	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVIDâ€19: Design and rationale for the DAREâ€19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896.	4.4	40
7	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 89-99.	4.1	18
8	A Survey of Aspirin Knowledge Among the General Public. Journal of General Internal Medicine, 2021, , 1.	2.6	1
9	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 586-594.	11.4	145
10	Proteomic Signatures of HeartÂFailureÂinÂRelation to LeftÂVentricular Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 1982-1994.	2.8	61
11	Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. Circulation, 2020, 141, 1463-1476.	1.6	42
12	NO to Lysosomes: A Signal for Insulin Resistance in Obesity. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 153-154.	4.5	1
13	Simple nutrients bypass the requirement for HLH-30 in coupling lysosomal nutrient sensing to survival. PLoS Biology, 2019, 17, e3000245.	5.6	17
14	Transcription Factor EB Activation Rescues Advanced Î±Bâ€Crystallin Mutationâ€Induced Cardiomyopathy by Normalizing Desmin Localization. Journal of the American Heart Association, 2019, 8, e010866.	3.7	47
15	TFEB activation in macrophages attenuates postmyocardial infarction ventricular dysfunction independently of ATG5-mediated autophagy. JCI Insight, 2019, 4, .	5.0	39
16	Cholesterol efflux in the transplant patient. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 143-146.	2.3	3
17	Fatal accelerated rejection with a prominent natural killer cell infiltrate in a heart transplant recipient with peripartum cardiomyopathy. Transplant Immunology, 2018, 47, 49-54.	1.2	1
18	Lysosomes Mediate Benefits of Intermittent Fasting in Cardiometabolic Disease: The Janitor Is the Undercover Boss. , 2018, 8, 1639-1667.		15

#	Article	IF	Citations
19	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports, 2017, 19, 1456-1466.	6.4	36
20	Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis. Nature Communications, 2017, 8, 15750.	12.8	258
21	Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. Autophagy, 2017, 13, 1952-1968.	9.1	131
22	How to Approach the Assessment of Cardiac Allograft Vasculopathy in the Modern Era: Review of Invasive Imaging Modalities. Current Heart Failure Reports, 2016, 13, 86-91.	3.3	7
23	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology, 2016, 118, 1855-1860.	1.6	15
24	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.6	12
25	Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation, 2016, 133, 706-716.	1.6	448
26	Carotid Intimaâ€Media Thickness Measurement Promises to Improve Cardiovascular Risk Evaluation in Head and Neck Cancer Patients. Clinical Cardiology, 2015, 38, 280-284.	1.8	8
27	Reconstituted High-Density Lipoprotein Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1800-1802.	2.4	7
28	Statin Therapy in Heart Failure. Hypertension, 2014, 63, 909-910.	2.7	5
29	Apolipoprotein A-I and Cholesterol Efflux. Circulation Research, 2014, 114, 1681-1683.	4.5	17
30	Sleep Apnea, Heart Failure, and Pulmonary Hypertension. Current Heart Failure Reports, 2013, 10, 315-320.	3.3	63
31	High-Density Lipoprotein. Circulation Research, 2013, 113, 1275-1277.	4.5	3
32	Constrictive Pericarditis Presenting as a Late Complication of Epicardial Ventricular Tachycardia Ablation. Circulation: Heart Failure, 2012, 5, e22-3.	3.9	19
33	Non-Catalytic Function for ATR in the Checkpoint Response. Cell Cycle, 2007, 6, 2019-2030.	2.6	7
34	CDK Pho85 targets CDK inhibitor Sic1 to relieve yeast G1 checkpoint arrest after DNA damage. Nature Structural and Molecular Biology, 2006, 13, 908-914.	8.2	36
35	γ-H2AX as a Therapeutic Target for Improving the Efficacy of Radiation Therapy. Current Cancer Drug Targets, 2006, 6, 197-205.	1.6	62
36	Yeast G1 DNA damage checkpoint regulation by H2A phosphorylation is independent of chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13771-13776.	7.1	77

#	Article	IF	Citations
37	Role of Dot1-Dependent Histone H3 Methylation in G1 and S Phase DNA Damage Checkpoint Functions of Rad9. Molecular and Cellular Biology, 2005, 25, 8430-8443.	2.3	268
38	Binding of Chromatin-Modifying Activities to Phosphorylated Histone H2A at DNA Damage Sites. Molecular Cell, 2004, 16, 979-990.	9.7	513